Scientists test Two-Pronged attack on spreading lung cancer
NCT ID NCT02812667
Summary
This early-stage study tested the safety of combining an experimental drug, plinabulin, with an approved immunotherapy, nivolumab, for people with advanced non-small cell lung cancer that had spread. The main goal was to find the highest dose of the combination that patients could tolerate without severe side effects. Researchers also wanted to see early signs of whether the combination could help shrink tumors or slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.